Journal of Cancer Therapy

Volume 1, Issue 3 (September 2010)

ISSN Print: 2151-1934   ISSN Online: 2151-1942

Google-based Impact Factor: 0.35  Citations  

Genetic Polymorphisms of Hepatic ABC-Transporter in Patients with Hepatocellular Carcinoma

HTML  Download Download as PDF (Size: 247KB)  PP. 114-123  
DOI: 10.4236/jct.2010.13019    4,778 Downloads   9,785 Views  Citations

Affiliation(s)

.

ABSTRACT

We examined whether genetic polymorphisms of efflux transporters in hepatocytes are associated with susceptibility to develop hepatocellular carcinoma (HCC). Genetic polymorphisms of drug transporters expressed in hepatocytes were analyzed using DNA samples from hepatitis C virus (HCV)-seropositive cirrhotic patients with HCC (n = 58), and allele and haplotype frequencies were compared with those in healthy subjects (n = 61). To search for single nucleotide polymorphisms (SNPs) in HCC susceptibility genes, 34 SNPs in 6 efflux transporters [MDR1 (ABCB1), ABCC1, ABCC2, ABCC3, ABCG2 and ABCB11] were determined. No significant association was observed for any single SNP; however, some haplotypes in ABCC1 and ABCB11 were associated with HCC. Furthermore, three combinations of SNPs (3435C > T in ABCB1 and 825T > C in ABCC1), (3435C > T in ABCB1 and -15281_-15278CTCT > delete in ABCB11), and (825T > C in ABCC1 and -15281_-15278CTCT > delete in ABCB11) were significantly associated with HCC. The present study suggests that genetic variations of ABC transporters such as ABCB1, ABCB11, and ABCC1 are associated with susceptibility to develop HCC, implying that aberrant hepatic clearance of toxic substances may increase the risk of hepatocarcinogenesis. Further studies of how these polymor-phisms are associated with phenotypic differences are warranted.

Share and Cite:

Fukuda, M. , Kawahara, Y. , Hirota, T. , Akizuki, S. , Shigeto, S. , Nakajima, H. , Ieiri, I. and Ohnishi, A. (2010) Genetic Polymorphisms of Hepatic ABC-Transporter in Patients with Hepatocellular Carcinoma. Journal of Cancer Therapy, 1, 114-123. doi: 10.4236/jct.2010.13019.

Cited by

[1] Prevalence of ABCC3‐1767G/A polymorphism among patients with antiretroviral‐associated hepatotoxicity
2020
[2] Bile salt export pump, arginase 1, and hepatocyte paraffin 1 expression in differential diagnosis of hepatocellular carcinoma from nonhepatocellular …
2019
[3] A meta-analysis of MDR1 polymorphisms rs1128503 and rs1045642 and susceptibility to hepatocellular carcinoma
2019
[4] Charakterizace nových inhibitorů cyklin-dependentních kinas v modelu hepatocelulárního karcinomu
THESIS, 2018
[5] Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study
Cancer Chemotherapy and Pharmacology, 2017
[6] Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer …
Cancer Chemotherapy and Pharmacology, 2017
[7] INTERACTIONS ENTRE THERAPIES CIBLEES ANTI-ANGIOGÉNIQUES (BEVACIZUMAB, SORAFÉNIB) ET TRANSPORTEURS D'EFFLUX
Thèse, 2017
[8] Genetic polymorphisms of the multidrug resistance 1 gene MDR1 and the risk of hepatocellular carcinoma
Tumor Biology, 2015
[9] Polimorfizmi ABC transportera i njihova uloga u tumorskim stanicama
2014
[10] Targeted inhibition of the FGF 19‐FGFR 4 pathway in hepatocellular carcinoma; translational safety considerations
Liver International, 2014
[11] Targeted inhibition of the FGF19‐FGFR4 pathway in hepatocellular carcinoma; translational safety considerations
Liver International, 2014
[12] Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma
Hepatology, 2013

Copyright © 2025 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.